GENX — Genix Pharmaceuticals Cashflow Statement
0.000.00%
- CA$1.78m
- CA$2.94m
- CA$0.00m
Annual cashflow statement for Genix Pharmaceuticals, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 October 31st | 2024 October 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -0.719 | -1.65 | -1.07 | -4.4 | -0.073 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 0.097 | 0.811 | 0.296 | 3.57 | -0.145 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.065 | -0.124 | -0.006 | 0.056 | 0.03 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Cash from Operating Activities | -0.195 | -0.428 | -0.22 | -0.221 | -0.187 |
Capital Expenditures | -0.008 | 0 | -0.003 | 0 | — |
Purchase / Acquisition of Intangibles | |||||
Cash from Investing Activities | -0.008 | 0 | -0.003 | 0 | — |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.868 | -0.129 | 0.093 | 0.223 | 0.187 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.665 | -0.558 | -0.13 | 0.002 | -0 |